ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.
A wave of risk aversion sweeps global markets, dragging cryptocurrencies down sharply. Bitcoin's technical breakdown and a steep drop for Worldcoin highlight a day of heavy losses and liquidations.
Shares of communications testing firm Viavi Solutions surged over 17% to a level not seen since 2002, as investors cheered a new restructuring initiative aimed at saving $30 million annually, despite the company posting a quarterly net loss.
LendingClub Corp. (LC) shares tumbled sharply this week, extending losses for a third consecutive session after the company announced a shift to fair value accounting. The move, aimed at aligning revenue with credit costs, spooked investors despite the fintech firm reporting a 164% surge in annual net income.
PUMA SE (XTRA:PUM) presents a complex picture for investors. While recent quarterly momentum has lifted shares, a deep dive reveals persistent losses and multi-year underperformance, raising questions about its true valuation and path to sustained profitability.
After years of lackluster performance, Digistar Corporation Berhad (KLSE:DIGISTA) is showing early signs of a operational turnaround, marked by a notable improvement in its return on capital employed. While still trailing the industry average, the shift from losses to profitability on a reduced capital base offers a glimmer of hope for the battered stock.
Klarna Group confronts a wave of class action lawsuits alleging it downplayed rising loan loss risks in its buy-now-pay-later portfolio ahead of its 2025 NYSE debut. The legal challenges cast a shadow over the fintech's post-IPO performance and have sparked a broader debate about transparency in the rapidly growing BNPL sector.
Wall Street maintains a positive stance on American Tower Corporation (AMT) as it enters 2026, with over 70% of analysts recommending the stock. While several firms have trimmed price targets citing sector headwinds, the long-term outlook for the communications infrastructure giant remains favorable, driven by its data center portfolio and stable tower business.
Amgen has terminated its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab, handing full development rights back to the Japanese partner. The strategic shift comes as Amgen's stock trades above most fair value estimates, raising questions about its current valuation amid pipeline recalibration.
Nurix Therapeutics, a clinical-stage biopharma company, is gaining attention for its novel protein degradation platform. With strong early data for its lead drug, key regulatory designations, and strategic partnerships with industry giants, the company is positioning itself to address unmet needs in multi-billion dollar oncology markets.
Investor and TV personality Kevin O'Leary has thrown his weight behind a proposed national child investment account policy, framing it as a bipartisan solution to America's widespread financial illiteracy and a foundational tool for building generational wealth.
As Archer Aviation advances toward FAA certification for its Midnight air taxi, bullish investors point to its strong liquidity and strategic partnerships. But with the company still pre-revenue and burning cash, the path to commercial launch by 2026 remains a high-stakes race against time and regulation.
The swearing-in of Rep. Christian Menefee (D-Texas) on Monday tightens the House margin to 218-214, leaving Speaker Mike Johnson with virtually no room for error on key votes, starting with this week's critical government funding bill.
Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.
Shares in Japanese electronics component maker TDK Corp. jumped over 11% after the company lifted its full-year profit outlook, powered by strong sales to smartphone makers and steady data center demand, easing investor concerns over memory market volatility.
The House is poised to vote Tuesday on a Senate-passed funding package to reopen most federal agencies, while a two-week stopgap for the Department of Homeland Security sets the stage for a fierce immigration policy battle.
While aggressively deploying AI across its vast logistics network, FedEx is taking a measured, pilot-stage approach to warehouse automation and drones, CEO Raj Subramaniam tells The New York Times. The shipping giant, handling $2 trillion in global commerce, prioritizes scalable infrastructure over unproven robotics for its 17 million daily packages.
DaVita Inc. reported Q4 2025 results in line with expectations, highlighting a milestone first profitable year for its Integrated Kidney Care unit. While revenue per treatment accelerated, the company continues to face pressure from elevated patient mortality and rising benefit costs. Executives provided 2026 guidance projecting mid-single-digit operating income growth and a sharp rise in EPS, buoyed by share buybacks and the stabilization of prior investment losses.
Simon Property Group reported robust fourth-quarter results, driven by record funds from operations and resilient leasing demand. The retail REIT giant is steering a multi-billion dollar redevelopment strategy while returning significant capital to shareholders, even as it navigates a cautious outlook for 2026.
Alphabet's autonomous vehicle unit Waymo is reportedly in talks to raise approximately $16 billion in a new financing round, which would value the company close to $110 billion. The move comes as the robotaxi pioneer faces heightened regulatory and public scrutiny following recent incidents involving its vehicles.
